As exosomes have emerged as a next-generation therapeutic platform for multiple diseases, leaders in the RNA community are now focusing on these nanoparticles as the ultimate drug delivery system for a wide range of indications from oncology to dermatology. NurExone has taken a unique approach and is using exosome therapies for regenerative medicine to develop promising therapies for central nervous system (CNS) injury. In this Q&A, Advancing RNA’s Acquisition Editor Michael Soloway caught up with NurExone Biologic’s CEO, Lior Shaltiel, Ph.D., to discuss the company’s approach to RNA therapeutics.
